Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iocarmic acid is a water-soluble, ionic, dimeric, high-osmolar iodinated contrast medium (HOCM) used historically for X-ray imaging. It contains six iodine atoms per molecule, providing the radiopacity required for diagnostic visualization. Developed in the 1960s and used primarily in the 1970s and 1980s, it was commonly administered as the meglumine salt (meglumine iocarmate). Its primary applications included myelography (imaging of the spinal cord), ventriculography, and hysterosalpingography. While considered better tolerated than some contemporary agents of its era, it has largely been superseded by non-ionic, low-osmolar contrast media (LOCM) which offer improved safety profiles, particularly regarding neurotoxicity and osmolality-related side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iocarmic acid.